Mitomycin Medac (Mitomycin)

Mitomycin is a bioreductive alkylating agent that, after activation in low‑oxygen tumour cells, forms covalent cross‑links between DNA strands. This blocks DNA replication and transcription, leading to cell cycle arrest and apoptosis of rapidly dividing cancer cells.

The dose of Mitomycin Medac is individualized by the prescribing oncologist based on the specific cancer type, treatment regimen, patient weight, renal and hepatic function, and other clinical factors. No fixed public dosing schedule is provided.

Mitomycin is classified as contraindicated in pregnancy and breastfeeding because it can cross the placenta and be excreted in breast milk, posing a risk to the fetus or infant. Women of child‑bearing potential should use effective contraception and discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed) and necessary import documentation.

Mitomycin belongs to the same class as other DNA‑cross‑linking agents such as dacarbazine and streptozocin, but it is distinguished by its activation under hypoxic conditions and its use both intravenously and intravesically. Its efficacy profile is comparable, while its toxicity spectrum includes notable renal and pulmonary risks that require specific monitoring.

Mitomycin Medac should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. The product should remain in its original packaging until ready for preparation and administration.

The drug is supplied as a sterile solution for intravenous infusion or intravesical instillation. Intravenous administration is performed by a qualified healthcare professional using aseptic technique, while intravesical use involves direct instillation into the bladder after catheterisation, typically following tumour resection.

Serious risks include severe myelosuppression leading to infection or bleeding, pulmonary toxicity such as interstitial pneumonitis or fibrosis, acute renal failure especially after intravesical use, and rare secondary malignancies. Patients should be monitored closely for signs of infection, respiratory distress, and renal dysfunction.

Mitomycin Medac is contraindicated in patients with known hypersensitivity to Mitomycin or related compounds, in those with severe renal or hepatic impairment, in pregnant or breastfeeding women, and in individuals receiving other agents that cause profound bone‑marrow suppression without appropriate dose adjustments.